Omecamtiv mecarbil, a cardiac-specific myosin activator, is being tested for treating left ventricle systolic heart failure. Myosin is present in “fast” and “slow” ATP-hydrolyzing forms; heart disease patients are often deficient in the fast form. Omecamtiv mecarbil binds to both forms to boost ATP hydrolysis and therefore heart function.
Learn more about this molecule from CAS, the most authoritative and comprehensive source for chemical information.
Stay Ahead of the Chemistry Curve
Learn how ACS can help you stay ahead in the world of chemistry.